[Multi-center trial on the early effects of silodosin on lower urinary tract symptoms associated with benign prostatic hyperplasia].
作者信息
Ogawa Takehiko, Uemura Hiroji, Sano Futoshi, Hoshino Kouji, Kita Kaoru, Hayashi Narihiko, Kagota Masayo, Murakami Takayuki, Makiyama Kazuhide, Miyoshii Yasuhide, Nakaigawa Noboru, Yao Masahiro, Shimura Hidetoshi, Furuhata Akihiko, Fujikawa Naoya, Shioi Koichi, Ueki Teiichiro, Hara Yoshinori, Saitou Kiyoshi, Kawakami Satoshi, Satomi Yoshiaki, Hattori Yusuke, Teranishi Junichi, Kondo Keiichi, Kishida Takeshi, Saito Kazuo, Noguchi Kazumi, Fuji Hiroshi, Yamaguchi Toyoaki, Kinoshita Yuzo, Nomura Sakae, Yoshida Minoru, Sakai Naoki, Terao Hideyuki, Matsumoto Tatsuya, Umemoto Susumu, Ogo Yoshiharu, Kobayashi Kazuki, Noguchi Sumio, Asakura Tomoyuki, Kohdaira Teruo, Iguchi Kozue, Izumi Koji, Hirano Masami, Kanno Hitomi, Takahashi Toshihiro, Nukui Fumihiko, Mokuo Yasuhiro, Muraoka Kentaro, Osada Yutaka, Funahashi Makoto, Kitami Kazuo, Sugiura Shimpei, Ohta Junichi, Miura Takeshi, Ishibashi Yoshio, Masuda Mitsunobu, Komiya Atsushi, Suwa Yutaka, Hashiba Takafumi, Mitaka Kunihisa, Kobayashi Masataka, Ohsaka Kimito, Futoshi Takano, Tsuchiya Tetsuzo, Iwasaki Akira, Yamashita Yuzo, Matsuzaki Junichi, Kubota Yoshinobu
机构信息
The Department of Urology, Yokohama City Univercity Graduate School of Medicine.
出版信息
Hinyokika Kiyo. 2008 Dec;54(12):757-64.
Silodosin (URIEF), a new so-called 3rd generation alpha-1 blocker, is widely expected to be effective and useful for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), due to its high specificity to alpha-1A receptor. We evaluated the efficacy of Silodosin, on 187 males 50 years old or over with the diagnosis of BPH. Silodosin significantly improved the International Prostate Symptom Score (IPSS) and quality of life (QOL) score from the day after administration was started. Among 166 patients whose data were available for the analysis of efficacy of Silodosin, 77.5% showed apparent subjective improvement. Eighty three patients, who had been taking another alpha-1 blocker but without satisfactory effects, showed almost the same improvements in IPSS and QOL score after switching to Silodosin as the remaining 83 patients who had no preceding treatment with an alpha-1 blocker. The improvements were not only in voiding symptoms but also in storage symptoms. The patients, who had serious storage symptoms, responded rather well to Silodosin and showed significant improvement. Taken together, Silodosin showed a quick effect for improving subjective symptoms and QOL, and was found to be useful for the management of LUTS with BPH.
Zotero 插件